Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo

Cancer Letters

Volumn 139, Issue 1, 1999, Pages 115-119

  Szabó, Diána ^a   Szabó Jr , Gábor ^b   Ocsovszki, Imre ^a   Aszalos, Adorján ^c   Molnár, József ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Amitriptyline; Cyclosporin A; Desipramine; Fluphenazine; Haloperidol; Imipramine; In patients; In vitro; In vivo; Maprotiline; Multidrug resistance; Reversal; Trimipramine

Indexed keywords

ANTINEOPLASTIC AGENT; BUTACLAMOL; CHLORPROMAZINE; CLOZAPINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DESIPRAMINE; DOXEPIN; DOXORUBICIN; FLUPHENAZINE; GLYCOPROTEIN P; HALOPERIDOL; IMIPRAMINE; MAPROTILINE; MULTIDRUG RESISTANCE PROTEIN; NEUROLEPTIC AGENT; PREDNISOLONE; RHODAMINE 123; TIOGUANINE; TRIFLUOPERAZINE; TRIMIPRAMINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

ANTIPSYCHOTIC AGENTS; CYCLOSPORINE; DAUNORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID; P-GLYCOPROTEIN; RHODAMINE 123; TUMOR CELLS, CULTURED;

EID: 0032958446     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00020-8     Document Type: Article

References (19)

1. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
2. Preisler H.D. Multidrug resistance is more than MDR1 activity. Leukemia Res. 19(7):1995;429-431.
3. Dicato M., Duhem C., Pauly M., Ries F. Multidrug resistance: molecular and clinical aspects. Cytokines Cell. Mol. Ther. 3:1997;91-100.
4. Cole R.M., Robinson F., Harvey L., Trethowan K., Murdoch V. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. J. Pain Symptom Manage. 9:1994;48-50.
5. Stiefel F., Holland J. Delirium in cancer patients. Int. Psychogeriatr. 3:1991;333-336.
6. Vecht C.J., Hoff A.M., Kansen P.J., de-Boer M.F., Bosch D.A. Types and causes of pain in cancer of the head and neck. Cancer. 70:1992;178-184.
7. Schinkel A.H., Wagenaar E., Mol C.A.A.M., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97(11):1996;2517-2524.
8. Molnár J., Sohár I., Kovács J., Rakonczay Z., Rausch H. Effect of tricyclic compounds on membrane binding of bivalent cations, activities of acetylcholinesterase and some tissue proteases. In Vivo. 7:1993;431-434.
9. Ford J.M., Prozialeck W.C., Hait W.N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 35:1989;105-115.
10. Szabó D., Molnár J. The role of stereoselectivity of chemosensitizers in the reversal of multidrug resistance of mouse lymphoma cells. Anticancer Res. 18:1998;3039-3044.
11. Glassman A.H., Perel J.M. Tricyclic blood levels and clinical outcome: a review of the art. Lipton A.M., DiMascic A., Killam K.F. Psychopharmacology, a Generation of Progress. 1978;917-921 Raven, New York.
12. Lee J.S., Paull K., Alvarez M., Hose C., Monks A., Grever M., Fojo A.T., Bates S.E. Rhodamin efflux patterns predict P-glycoprotein substrates in the national cancer institute drug screen. Mol. Pharmacol. 46:1994;627-638.
13. Sridhar K.S., Krishan A., Samy T.S.A., Duncan R.C., Sauerteig A., McPhee G.V., Auguste M.E., Benedetto P.W. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. Cancer Chemother. Pharmacol. 34:1994;377-384.
14. Aszalos A., Pine P.S., Weaver J.L., Rao P.E. Cytochalasin D modulates CD4 crosslinking sensitive mitogenic signal in T lymphocytes. Cell. Immunol. 157:1994;81-91.
15. Aszalos A., Pine P.S., Pandey R., Gottesman M.M. Behavior of N-acylated daunorubicins in MDR1 gene transfected and parental cells. Biochem. Pharmacol. 50:1995;889-892.
16. Weaver J.L., Pine P.S., Aszalos A., Schoenlein P.V., Currier S.J., Padmanabhan R., Gottesman M.M. Laser scanning and confocal microscopy of daunorubicin, doxorubicin and rhodamin 123 in multidrug-resistant cells. Exp. Cell Res. 196:1991;323-329.
17. Weaver J.L., Szabó G. Jr., Pine P.S., Gottesman M.M., Goldenberg S., Aszalos A. The effect of ion channel blockers, immunosuppressive agents and other drugs on the activity of the multidrug transporter. Int. J. Cancer. 54:1993;456-461.
18. Ford J.M., Bruggemann E.P., Pastan I., Gottesman M.M., Hait W.N. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 50:1991;1748-1756.
19. Baldessarini R.J., Cohen B.M., Teicher M.H. Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses. Arch. Gen. Psychiatry. 45:1988;79-91.